ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1418 • 2016 ACR/ARHP Annual Meeting

    Rheumatologist: If You Fell Ill with Seropositive Active Rheumatoid Arthritis Yourself, What to Do!

    Kalle Aaltonen1, Elena Nikiphorou2,3, Nasim A. Khan4 and Tuulikki Sokka5, 1Helsinki University, Helsinki, Finland, 2Whittington Hospital, London, United Kingdom, 3Jyväskylä Central Hospital, Jyväskylä, Finland, 4Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 5Jyvaskyla Central Hospital, Jyväskylä, Finland

    Background/Purpose: International and national bodies have given evidence-based recommendations for rheumatoid arthritis (RA) treatment. We assessed the general uptake of these recommendations by asking rheumatologists…
  • Abstract Number: 1419 • 2016 ACR/ARHP Annual Meeting

    Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients

    Hervé Devilliers1, Meenakshi Jolly2, Maxime Samson3, Bernard Bonnotte4, Francois Maurier5, Pascal Sève6, Nadine Magy-Bertrand7, Denis Wahl8, Jean-Loup Pennaforte9, Thierry Martin10, Olivier Aumaître11, Gilles Blaison12, Philip Bielefeld13, Alexis Mathian14, Christine Binquet15 and Zahir Amoura14, 1Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 2Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, 3Dijon University Hospital, Dijon, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, 6Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 7CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, 8CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, 9Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 10Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, 11Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 12Internal medicine departement, Colmar Hospital, Colmar, France, 13Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, 14Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 15INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France

    Background/Purpose: To assess validity and reliability of French LupusPRO in France. Methods: After cross-cultural adaptation and harmonization for France, the LupusPRO was administered along with…
  • Abstract Number: 1420 • 2016 ACR/ARHP Annual Meeting

    Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

    Meenakshi Jolly1, Nisarg Gandhi2, Winston Sequeira2 and Joel Block2, 1Rush, Chicago, IL, 2Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Disease Specific Patient reported outcome measures capture unique domains relevant to patients with a specific disease. LupusPRO is targeted towards measuring health (HRQOL) and…
  • Abstract Number: 1421 • 2016 ACR/ARHP Annual Meeting

    Responsiveness of Lupus Impact Tracker Among Chinese Patients with Lupus

    Chi Chiu Mok1, Meenakshi Jolly2 and Joel Block3, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Rush, Chicago, IL, 3Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Lupus Impact Tracker (LIT), a 10 item, patient reported outcome tool for patients with systemic lupus erythematosus (SLE) has undergone psychometric validation and responsiveness…
  • Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting

    Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study

    Tanja Schjødt Jørgensen1, Louise Klokker1, Henrik Gudbergsen2, Simon Francis Thomsen3, Robin Christensen4, Henning Bliddal1 and Lars Erik Kristensen1, 1The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, 2The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg,, Copenhagen, Denmark, 3Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 4Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark

    Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…
  • Abstract Number: 1423 • 2016 ACR/ARHP Annual Meeting

    Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis

    Stephen Doogan1, John Heid2, Samir Benosman3, Alexis Ogdie4, Layne Martin5, Prashanth Sunkureddi6 and Jacqueline Palmer7, 1Real Life Sciences, New York, NY, 2Kinapse, Inc, London, United Kingdom, 3Advisory Services, Kinapse, Inc, London, United Kingdom, 4University of Pennsylvania, Philadelphia, PA, 5CreakyJoints, NY, 6Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose:  Psoriatic Arthritis (PsA) is a debilitating disease with significant impact on patient quality of life (QoL).  While patient reported outcome (PRO) instruments broadly capture…
  • Abstract Number: 1424 • 2016 ACR/ARHP Annual Meeting

    Acceptability of a Connected Activity Tracker in 92 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA): A 3-Months Study

    Charlotte Jacquemin1, Herve Servy2, Anna Molto3, Jeremie Sellam4, Violaine Foltz1, Frédérique Gandjbakhch1, Christophe Hudry3, Stéphane Mitrovic1, Bruno Fautrel1 and Laure Gossec1, 1Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 2Sanoia, La Ciotat, France, 3Rheumatology, Cochin Hospital, Paris, France, 4Rheumatology, Saint-Antoine Hospital, Paris, France

    Background/Purpose: Physical activity is recommended and is an important part of the management of inflammatory arthritis and in particular RA and axSpA. Activity trackers, and…
  • Abstract Number: 1425 • 2016 ACR/ARHP Annual Meeting

    Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)

    Clare Longton1, Marco Massarotti2 and Marwan Bukhari3, 1Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, 2Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, 3Royal Lancaster Infirmary, Lancaster, United Kingdom

    Background/Purpose: Improving patient experience is important in all diseases, but most important in patients with chronic rheumatic diseases like the axial spondyloarthropathies (AxSpa). The Commissioning…
  • Abstract Number: 1426 • 2016 ACR/ARHP Annual Meeting

    Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis

    Prashanth Sunkureddi1, Dawn Gibson2, Stephen Doogan3, John Heid4, Samir Benosman5 and Yujin Park6, 1Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, 2The Global Healthy Living Foundation, Upper Nyack, NY, 3Real Life Sciences, New York, NY, 4Kinapse, Inc, London, United Kingdom, 5Advisory Services, Kinapse, Inc, London, United Kingdom, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spinal joints that can lead to severe, chronic pain and discomfort. There is a…
  • Abstract Number: 1427 • 2016 ACR/ARHP Annual Meeting

    The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort

    Sergio Schwartzman1, Keith Knapp2, Gary Craig3 and Discus, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Arthritis Northwest PLLC., Spokane, WA, 3Discus Analytics LLC., Spokane, WA

    Background/Purpose: Outcome measures in AS are well established in clinical trial settings but infrequently used in real-world (RW) practice.  These measures include the BASDAI, BASFI,…
  • Abstract Number: 1428 • 2016 ACR/ARHP Annual Meeting

    Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany

    James Piercy1, John Waller1, Emma Sullivan1, Christopher Black2 and Sumesh Kachroo2, 1Adelphi Real World, Manchester, United Kingdom, 2CORE, Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: Our aim is to address the lack of understanding surrounding patient attitudes to being prescribed biosimilars in the real world for Rheumatoid Arthritis (RA),…
  • Abstract Number: 1429 • 2016 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes Measures and Economical Burden of Patients with Ankylosing Spondylitis in a Chinese Prospective Cohort with Smart Management System for Spondyloarthritis

    Qiongfang Wen, Xiaojian Ji, Jinshui Yang, Jian Zhu, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China

    Background/Purpose: Ankylosing Spondylitis (AS) is characterized by relatively young onset age, easily causing spinal deformity and stiffness, and seriously influencing the health related Quality of…
  • Abstract Number: 1430 • 2016 ACR/ARHP Annual Meeting

    Adherence to the International Consensus Quality Indicators for Longitudinal Health Maintenance and Preventative Care in a Pediatric Rheumatology Clinic

    Abigail Bosk, Barbara Edelheit, Lawrence Zemel and Heather Tory, Rheumatology, Connecticut Children's Medical Center, Hartford, CT

    Background/Purpose: Juvenile systemic lupus erythematosus (jSLE) is a chronic disease associated with significant morbidity. Variability in the health maintenance-related management of these patients can contribute…
  • Abstract Number: 1431 • 2016 ACR/ARHP Annual Meeting

    Estimates of Global Status By Physicians and Patients Are More Likely to be Discordant in Osteoarthritis Than in Rheumatoid Arthritis

    Isabel Castrejón1, Joel Block2 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Division of Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Concordant 0-10 estimates of global status by physicians (DOCGL) and patients (PATGL) are associated with greater expectations for improvement and better outcomes1, and appear…
  • Abstract Number: 1432 • 2016 ACR/ARHP Annual Meeting

    The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development

    Rucsandra Dobrota1, Mike Becker2, Kim Fligelstone3,4, Jaap Fransen5, Ann Kennedy6, Yannick Allanore7, Patricia Carreira8, László Czirják9, Christopher Denton10, Roger Hesselstrand11, Gunnel Sandqvist11, Otylia Kowal-Bielecka12, Marco Matucci Cerinic13, Carina Mihai14, Ana Maria Gheorghiu15, Ulf Müller-Ladner16, Marc Frerix17, Turid Heiberg18 and Oliver Distler1, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 4Federation of European Scleroderma Associations (FESCA), London, United Kingdom, 5Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 6Federation of European Scleroderma Associations (FESCA), Tournai, Belgium, 7Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, 8Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 9Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, 10Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 11Department of Rheumatology, Lund University, Lund, Sweden, 12Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 13Department of Rheumatology, University of Florence, Florence, Italy, 14Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania, 15Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, 16Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 17Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 18Department of Health and Social Sciences, Oestfold University College, Oslo, Norway

    Background/Purpose: Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc). A PROM tool in SSc,…
  • « Previous Page
  • 1
  • …
  • 1510
  • 1511
  • 1512
  • 1513
  • 1514
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology